Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

: CTIS2024-516402-32-00 Primary Outcome 1 - XML Representation

Page standards status: Informative

Raw xml | Download


<EvidenceVariable xmlns="http://hl7.org/fhir">
  <id value="346487"/>
  <meta>
    <versionId value="2"/>
    <lastUpdated value="2025-03-05T19:33:28.216Z"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: EvidenceVariable 346487</b></p><a name="346487"> </a><a name="hc346487"> </a><a name="346487-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 2; Last updated: 2025-03-05 19:33:28+0000</p></div><p><b>url</b>: <a href="EvidenceVariable-346487.html">EvidenceVariable CTIS2024-516402-32-00 Primary Outcome 1</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/346487, FEvIR Linking Identifier/CTIS2024-516402-32-00 Primary Outcome 1, CTIS endPoint id/441508, <a href="http://terminology.hl7.org/6.2.0/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt 

This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: 

Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.

This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.24.4</p><p><b>version</b>: 1.0.0-ballot2</p><p><b>name</b>: CTIS2024_516402_32_00_Primary_Outcome_1</p><p><b>title</b>: CTIS2024-516402-32-00 Primary Outcome 1</p><p><b>status</b>: Active</p><p><b>date</b>: 2025-03-28 17:11:38+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>Response to therapy, defined by the absence of any of the following events: i) at 6-month follow-up: persistent renal replacement therapy, eGFR&lt;15ml/mn/1,73m2, or patient death; ii) at W2 : persistent hemolysis despite well conducted antihypertensive therapy. Any Eculizumab rescue in the control group will be considered as a failure.</p>
</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>author</b>: Brian S. Alper, MD, MSPH: </p></div>
  </text>
  <url value="https://fevir.net/resources/EvidenceVariable/346487"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/346487"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="CTIS2024-516402-32-00 Primary Outcome 1"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="CTIS endPoint id"/>
    </type>
    <value value="441508"/>
  </identifier>
  <identifier>
    <system value="urn:ietf:rfc:3986"/>
    <value value="urn:oid:2.16.840.1.113883.4.642.40.44.24.4"/>
  </identifier>
  <version value="1.0.0-ballot2"/>
  <name value="CTIS2024_516402_32_00_Primary_Outcome_1"/>
  <title value="CTIS2024-516402-32-00 Primary Outcome 1"/>
  <status value="active"/>
  <date value="2025-03-28T17:11:38+00:00"/>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <description
               value="Response to therapy, defined by the absence of any of the following events: i) at 6-month follow-up: persistent renal replacement therapy, eGFR&lt;15ml/mn/1,73m2, or patient death; ii) at W2 : persistent hemolysis despite well conducted antihypertensive therapy. Any Eculizumab rescue in the control group will be considered as a failure."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <author>
    <name value="Brian S. Alper, MD, MSPH"/>
  </author>
</EvidenceVariable>